Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients

PURPOSE: High Mobility Group Box 1 (HMGB1) protein has been described as a consensus marker for immunogenic cell death (ICD) in cancer. To personalize treatments, there is a need for biomarkers to adapt dose prescription, concomitant chemotherapy, and follow-up in radiation oncology. Thus, we invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Clasen, Kerstin, Welz, Stefan, Faltin, Heidrun, Zips, Daniel, Eckert, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789630/
https://www.ncbi.nlm.nih.gov/pubmed/34671818
http://dx.doi.org/10.1007/s00066-021-01860-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789630/
https://www.ncbi.nlm.nih.gov/pubmed/34671818
http://dx.doi.org/10.1007/s00066-021-01860-8

Ejemplares similares